Olmesartan and temocapril prevented the development of hyperglycemia and the deterioration of pancreatic islet morphology in Otsuka-Long-Evans-Tokushima Fatty rats

Masanobu Kaihara, Yoshio Nakamura, Taro Sugimoto, Haruhito A. Uchida, Hisanao Norii, Yoshihisa Hanayama, Hirofumi Makino

Research output: Contribution to journalArticle

8 Citations (Scopus)


We investigated the impact of olmesartan and temocapril on pancreatic islet β-cells during the development of diabetes mellitus using Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats. Four-week-old male OLETF rats were fed standard chow (untreated: n = 5), or chow containing either 0.005% olmesartan (n = 5) or 0.01 % temocapril (n = 5) until being sacrificed at 35 weeks of age. Pancreas sections were double-stained with anti-insulin and anti-glucagon antibodies. The percent areas of β-cells, α-cells and non-α-non-β-cells were compared among groups. In untreated OLETF rats, the fasting plasma glucose (FPG) level was elevated at the 18th week and remained elevated until the 35th week. On the other hand, no significant elevation in FPG levels was observed in olmesartan- or temocapril-treated rats. Pancreatic islets from olmesartan-treated rats were significantly smaller in size as compared with those from untreated OLETF rats. Furthermore, the average area occupied by α-cells as a fraction of the total area of an individual islet was significantly higher in olmesartan- or temocapril-treated rats than that in untreated OLETF rats. Olmesartan and temocapril both prevented the development of hyperglycemia, possibly through the prevention of islet β-cell loss in spontaneously diabetic OLETF rats.

Original languageEnglish
Pages (from-to)35-42
Number of pages8
JournalActa medica Okayama
Issue number1
Publication statusPublished - Feb 1 2009



  • Angiotensin II type-1 receptor blocker
  • Angiotensin converting enzyme inhibitor
  • Insulin secretion
  • Pancreas
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this